Sernova, Seraxis close US$ 11.2 million financing for planned BetaNova merger

Bitget2026/10/05 11:02

Sernova Biotherapeutics, Seraxis agreed to merge into BetaNova Biotherapeutics under a definitive deal signed Sept. 7, 2026. Companies closed a non-brokered convertible note financing into Seraxis totaling USD 11.2 million tied to the merger. On closing, Sernova, Seraxis shareholders expected to each hold about 50% of BetaNova on a non-diluted basis. Merger rationale centers on combining Seraxis’ stem cell-derived islet programs, cGMP manufacturing with Sernova’s Cell Pouch bio-hybrid organ platform. Financing proceeds earmarked for SR-02 manufacturing, a Phase 1/2 trial start in Q4, first dosing in Q1 2027, Nasdaq readiness in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839024) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Michael Saylor releases bitcoin Tracker information again, possibly hinting at increasing BTC holdings

BlockBeats•2026/10/11 12:13

Crypto Pundit Says If You Are Holding XLM, Read This

TimesTabloid•2026/10/11 12:00

International gold prices are approaching the $4,200 mark, and Wall Street is bullish on next week's market.

新浪财经•2026/10/11 11:05

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27